Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
about
Imaging of multiple myeloma: Current conceptsMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingMulti-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and OsteoblastsDasatinib as a bone-modifying agent: anabolic and anti-resorptive effectsRecent advances in antimultiple myeloma drug development.IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaMultiple myeloma and bone disease: pathogenesis and current therapeutic approaches.Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cellsMultiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsBone disease in multiple myeloma: pathophysiology and management.Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.A critical role for the NFkB pathway in multiple myeloma.CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone diseaseBortezomib in the management of multiple myeloma.Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.Molecular imaging in myeloma precursor disease.A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.Genetic factors influencing the risk of multiple myeloma bone diseaseDkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblastsHuman placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneBone anabolic agents for the treatment of multiple myeloma.Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease.Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche.Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis.The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cellsInvolvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.Bone marrow microenvironment and the identification of new targets for myeloma therapy.Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.Effect of pathologic fractures on survival in multiple myeloma patients: a case control studyThe roles of Wnt signaling modulators Dickkopf-1 (Dkk1) and Dickkopf-2 (Dkk2) and cell maturation state in osteogenesis on microstructured titanium surfaces.The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.Treatment strategies for bone disease.Cellular mechanisms of multiple myeloma bone diseaseGenetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myelomaMyeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma.Mechanisms of multiple myeloma bone disease.Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.
P2860
Q26864616-7AA1560C-E699-475B-8B6B-8BE3183F1AA8Q28082335-951CD944-5B52-43C8-96DF-C3F5E65B8D9CQ28551480-48D154C8-EFDF-48EB-B1F7-B4A7DB40B9D5Q28730433-212DCBE2-1ACB-4D37-8101-18920DBE768CQ33416297-8CCF99C5-CE10-415B-8187-4ABDFEF42755Q33574203-BBD8064A-7D98-4C8E-B3D4-D28B4E34C91CQ33856318-E1A5B48F-DADE-45AA-8F11-BDD5B7111266Q33953955-8637BE76-C67E-41AB-A343-C758EDA71185Q34022425-754AC2DD-1F0F-4F2C-B76B-A9C7C2D914B7Q34038854-63359DF9-35DC-4512-B696-B0B6F920F6D0Q34045789-ED1AD03D-7643-49B5-B6B0-99353A2DEAB2Q34155848-6612BC6F-317D-4CC3-A933-ABABF22518F6Q34165181-99815004-34BA-46C2-9A82-B0D4A5E12FBAQ34292995-04F7E097-E6C9-46EC-AC10-ABF48827EACCQ34418462-DDA09B77-C02D-4C9C-8AE7-CE0147237014Q34418934-F3454222-B00C-4966-B697-8D667215BC6EQ34505016-32B9AD19-738D-4552-8FBE-6A73EC1D577DQ34543089-77BCDD02-97C4-452F-ADB8-EC4D24E0EBC4Q34674841-616C41AA-9727-4A17-89E2-3A8BDBBE98ADQ35144762-83B905BA-E52D-44DB-876A-07ABFAAAA8BEQ35219019-FED82C92-1AE6-472F-8411-E1C6E9052ABCQ35603116-F228041C-F8B0-4B36-BA5F-FB012E89F341Q35631319-DDA57CA8-A38F-4C49-B7F5-3DA3501CDAB4Q35631433-320B543D-2137-46A8-AC78-E4CF19A2F681Q35770718-59A55DC3-3157-49C4-9415-A1F28C6E95EDQ35828711-9258B527-3702-4CEB-A408-7BB5461777AFQ35955440-F6A685E8-74BD-486D-B1FB-D69E131D4289Q36054631-9895EED6-B580-4EAF-9B8A-624F07BAEFA3Q36162703-1AD2B5E7-018E-4F04-BF1F-F7EDBCA034E9Q36589122-3BFFD92A-6FEF-46DF-B8C4-5C6F3AA35648Q36735008-59D1B827-40E5-4E28-9763-236262421563Q36745255-6078C777-4690-4B8E-86D3-ADFD60816070Q36870585-4C3DCCC6-2423-467D-8F8F-80A48210A574Q36902828-C36F7F98-FA95-4C21-9E16-26E7B57603E3Q36925346-FEEA3EFA-4A08-40CA-B9FC-1D8B62AD39A7Q36934224-02F20B1B-642E-4550-A489-AB8975E026ECQ37027406-88BAE771-EE41-43CD-98C5-C75357A939B6Q37056408-D7CE52C3-2335-4F1D-8062-C8FFC3C4A5E4Q37085867-775EE2CA-D152-4215-B087-71AAAC1C4B49Q37201872-2E4090F4-38B6-4F62-8B85-751B03C47B38
P2860
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
@ast
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
@en
type
label
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
@ast
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
@en
prefLabel
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
@ast
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
@en
P1433
P1476
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition
@en
P2093
G David Roodman
Vittorio Rizzoli
P304
P356
10.1182/BLOOD-2006-05-026112
P407
P577
2006-08-17T00:00:00Z